These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2868476)

  • 21. Early course of new-onset tardive dyskinesia in older patients.
    Lacro JP; Gilbert PL; Paulsen JS; Fell R; Bailey A; Juels C; Caligiuri M; McAdams LA; Harris MJ; Jeste DV
    Psychopharmacol Bull; 1994; 30(2):187-91. PubMed ID: 7831454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment.
    Byne W; White L; Parella M; Adams R; Harvey PD; Davis KL
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):473-9. PubMed ID: 9695037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia.
    Wu JQ; Chen DC; Xiu MH; Tan YL; Yang FD; Kosten TR; Zhang XY
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():71-7. PubMed ID: 23827756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology.
    Wegner JT; Catalano F; Gibralter J; Kane JM
    Arch Gen Psychiatry; 1985 Sep; 42(9):860-5. PubMed ID: 2864029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive sequelae of tardive dyskinesia.
    DeWolfe AS; Ryan JJ; Wolf ME
    J Nerv Ment Dis; 1988 May; 176(5):270-4. PubMed ID: 2896762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain atrophy and intellectual impairment in tardive dyskinesia.
    Ueyama K; Fukuzako H; Takeuchi K; Hirakawa K; Fukuzako T; Hokazono Y; Takigawa M; Matsumoto K
    Jpn J Psychiatry Neurol; 1993 Mar; 47(1):99-104. PubMed ID: 8105130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia in 2 patients treated with ziprasidone.
    Ananth J; Burgoyne KS; Niz D; Smith M
    J Psychiatry Neurosci; 2004 Nov; 29(6):467-9. PubMed ID: 15644988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach.
    Baribeau J; Laurent JP; Décary A
    Brain Cogn; 1993 Sep; 23(1):40-55. PubMed ID: 8105821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking and movement disorders in psychiatric patients.
    Menza MA; Grossman N; Van Horn M; Cody R; Forman N
    Biol Psychiatry; 1991 Jul; 30(2):109-15. PubMed ID: 1680470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective.
    Souza RP; Meltzer HY; Lieberman JA; Voineskos AN; Remington G; Kennedy JL
    Hum Psychopharmacol; 2011 Jan; 26(1):21-7. PubMed ID: 21305610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment.
    Dalgalarrondo P; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 1994; 244(5):272-7. PubMed ID: 7893773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical correlates of distinct topographies of tardive dyskinesia in schizophrenia.
    Waddington JL; Youssef HA; Kinsella A
    Am J Psychiatry; 1993 Nov; 150(11):1757-8. PubMed ID: 8105709
    [No Abstract]   [Full Text] [Related]  

  • 39. Psychopathological and cognitive correlates of tardive dyskinesia in patients treated with neuroleptics.
    Wonodi I; Hong LE; Thaker GK
    Adv Neurol; 2005; 96():336-49. PubMed ID: 16383230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive dysfunction and tardive dyskinesia.
    Struve FA; Willner AE
    Br J Psychiatry; 1983 Dec; 143():597-600. PubMed ID: 6140972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.